DBV Technologies (XPAR:DBV) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:DBV DBV Technologies SA XPAR:DBV
26 GF Score
Price €2.60
! 1 Warning Sign
View Full Analysis

What is DBV Technologies Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XPAR:DBV vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, DBV Technologies's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DBV Technologies Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DBV Technologies's Short Interest distribution charts can be found below:

* The bar in red indicates where DBV Technologies's Short Interest falls into.


XPAR:DBV
26GF Score
DBV Technologies SA XPAR:DBV
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DBV Technologies Business Description

Address 107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
26GF Score

Get the complete analysis for XPAR:DBV

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.60
Price